tiprankstipranks
Trending News
More News >
Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
US Market
Advertisement

Bavarian Nordic (BVNRY) Earnings Dates, Call Summary & Reports

Compare
174 Followers

Earnings Data

Report Date
Mar 12, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
Last Year’s EPS
0.47
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 14, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in both revenue and market expansion for Bavarian Nordic, especially in the Travel Health and Public Preparedness segments. However, there were some challenges related to the refinement of financial guidance and delays affecting the U.S. launch of the chikungunya vaccine.
Company Guidance
During the Bavarian Nordic conference call discussing the fiscal year 2025 third-quarter results, key financial metrics were highlighted. The company achieved close to DKK 4.8 billion in total revenues for the first nine months, marking a 32% increase compared to the same period last year. This growth was attributed to strong performances across both Travel Health and Public Preparedness segments, resulting in an EBITDA margin of 31%. The Travel Health business saw a 23% increase in sales, driven by robust growth in rabies and tick-borne encephalitis (TBE) vaccines, along with the successful launch of the chikungunya vaccine, Vimkunya. Meanwhile, the Public Preparedness segment recorded DKK 3.1 billion in secured contracts, surpassing the normal annual base business. The company's guidance was refined but remained within the initial range, with expectations of achieving DKK 6 billion in total revenue by year-end. The CEO, Paul Chaplin, emphasized that the refinement was not a lowering of guidance but a reflection of the secured business, with Travel Health expected to contribute DKK 2.75 billion. The call also highlighted the company's strategic focus on turning around acquired assets and the ongoing transformation into a profitable vaccine company.
Record-Breaking Revenue Growth
Bavarian Nordic achieved close to DKK 4.8 billion in total revenues, marking a 32% increase compared to the previous year. This growth was driven by strong performance across both Travel Health and Public Preparedness segments.
Travel Health Business Expansion
The Travel Health business experienced its strongest quarter, with a 23% increase in sales year-over-year. Key products such as rabies and tick-borne encephalitis (TBE) vaccines showed significant market share gains, particularly in the U.S. and Germany.
Successful Launch of Chikungunya Vaccine
The chikungunya vaccine, Vimkunya, was launched in 10 countries and is expected to meet the target of DKK 75 million in sales during its first launch year. Future growth potential is projected as the market could grow to $500 million annually.
Public Preparedness Revenue Surge
The Public Preparedness segment secured DKK 3.1 billion in revenue, which is DKK 1 billion higher than the normal annual base, due to increased government contracts and initiatives.

Bavarian Nordic (BVNRY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BVNRY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 12, 2026
2025 (Q4)
- / -
0.468
Nov 14, 2025
2025 (Q3)
- / 0.73
0.0441556.82% (+0.68)
Aug 22, 2025
2025 (Q2)
- / 0.24
0.16146.58% (+0.07)
May 09, 2025
2025 (Q1)
- / 0.13
-0.071285.92% (+0.20)
Mar 05, 2025
2024 (Q4)
- / 0.47
0.565-17.17% (-0.10)
Nov 15, 2024
2024 (Q3)
- / 0.04
-0.213120.66% (+0.26)
Aug 22, 2024
2024 (Q2)
- / 0.16
0.336-52.08% (-0.18)
May 08, 2024
2024 (Q1)
- / -0.07
0.232-130.60% (-0.30)
Feb 21, 2024
2023 (Q4)
- / 0.56
0.097482.47% (+0.47)
Nov 16, 2023
2023 (Q3)
- / -0.21
0.008-2762.50% (-0.22)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BVNRY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 14, 2025
$9.72$9.14-5.94%
Aug 22, 2025
$12.38$12.49+0.95%
May 09, 2025
$7.82$8.29+6.10%
Mar 05, 2025
$7.69$8.08+5.01%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bavarian Nordic A/S (BVNRY) report earnings?
Bavarian Nordic A/S (BVNRY) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).
    What is Bavarian Nordic A/S (BVNRY) earnings time?
    Bavarian Nordic A/S (BVNRY) earnings time is at Mar 12, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BVNRY EPS forecast?
          Currently, no data Available
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis